Sitagliptin + Placebo
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemia
Conditions
Hyperlipidemia
Trial Timeline
Jul 1, 2012 → Aug 1, 2013
NCT ID
NCT01600703About Sitagliptin + Placebo
Sitagliptin + Placebo is a phase 2/3 stage product being developed by Merck for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01600703. Target conditions include Hyperlipidemia.
What happened to similar drugs?
8 of 20 similar drugs in Hyperlipidemia were approved
Approved (8) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02536248 | Phase 3 | Completed |
| NCT02256189 | Approved | Completed |
| NCT02294084 | Approved | Completed |
| NCT02015910 | Approved | Terminated |
| NCT01928199 | Approved | Completed |
| NCT01859793 | Approved | Completed |
| NCT01600703 | Phase 2/3 | Completed |
| NCT01334229 | Phase 3 | Completed |
| NCT01272583 | Pre-clinical | Completed |
| NCT00790205 | Phase 3 | Completed |
| NCT00732121 | Approved | UNKNOWN |
| NCT00660075 | Phase 3 | Completed |
| NCT00501657 | Phase 1 | Completed |
Competing Products
20 competing products in Hyperlipidemia